Compare · BDX vs UFPT
BDX vs UFPT
Side-by-side comparison of Becton Dickinson and Company (BDX) and UFP Technologies Inc. (UFPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and UFPT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 23.6x UFPT ($1.75B).
- Over the past year, BDX is down 13.0% and UFPT is down 4.4% - UFPT leads by 8.5 points.
- UFPT has been more active in the news (17 items in the past 4 weeks vs 10 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 7 for UFPT).
- Company
- Becton Dickinson and Company
- UFP Technologies Inc.
- Price
- $150.14-0.71%
- $229.46+3.08%
- Market cap
- $41.33B
- $1.75B
- 1M return
- -2.01%
- +2.52%
- 1Y return
- -12.95%
- -4.43%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1993
- News (4w)
- 10
- 17
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
UFP Technologies Inc.
UFP Technologies, Inc. designs and converts foams, films, and plastics materials for the medical, automotive, consumer, electronics, industrial, and aerospace and defense markets in the United States. It offers single patient use surfaces, advanced wound care, infection prevention, and disposables for surgical procedures, endoscopic procedures, orthopedic implants, orthopedic appliances, biopharma drug manufacturing, etc.; molded components for automotive, aerospace, and defense markets; recycled protective packaging for B2C brands; and reusable cases and custom inserts. The company markets and sells its products through direct sales forces and independent manufacturer representatives. UFP Technologies, Inc. was founded in 1963 and is headquartered in Newburyport, Massachusetts.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest UFPT
- Executive Chairman Bailly R Jeffrey was granted 1,787 shares and covered exercise/tax liability with 750 shares, increasing direct ownership by 0.61% to 171,200 units (SEC Form 4)
- SVP Human Resources Stafford Ryan K was granted 1,448 shares (SEC Form 4)
- New insider Stafford Ryan K claimed no ownership of stock in the company (SEC Form 3)
- UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Financial Officer Lataille Ronald J was granted 4,454 shares, increasing direct ownership by 28% to 20,352 units (SEC Form 4)
- President Rock Mitchell was granted 2,895 shares, increasing direct ownership by 8% to 39,115 units (SEC Form 4)
- Director Hassett Joseph John was granted 802 shares, increasing direct ownership by 49% to 2,425 units (SEC Form 4)
- Director Hudson Symeria was granted 802 shares, increasing direct ownership by 70% to 1,955 units (SEC Form 4)
- Director Feldmann Cynthia L was granted 802 shares, increasing direct ownership by 17% to 5,476 units (SEC Form 4)
- Director Croteau Daniel C was granted 802 shares, increasing direct ownership by 94% to 1,657 units (SEC Form 4)